BioSpace News Archive

An FDA advisory committee on Friday agreed that using minimal residual disease could be a viable surrogate endpoint for accelerated approval for drug development in multiple myeloma.

AbbVie’s small molecule drug Qulipta has durable benefits and can reduce migraine frequency through 48 weeks of follow-up, according to interim Phase III data released on Friday.

While the VC fund launched on Monday by Regeneron Pharmaceuticals has an investment mandate that includes healthcare broadly, Regeneron Ventures will lean towards biotechnology, devices, tools and enabling technologies.

Roche said Monday that its bispecific T cell engager Columvi improved survival in a Phase III lymphoma trial, clearing the drugmaker to seek a full, expanded label that could drive sales growth.

While Madrigal Pharmaceuticals secured the first FDA drug approval for metabolic dysfunction–associated steatohepatitis, Akero Therapeutics is developing what may serve as a viable alternative treatment for precirrhotic disease.

Following cases of convulsions in rabbits in a preclinical study, the FDA has placed a clinical hold on Neumora Therapeutics’ Phase I schizophrenia drug candidate NMRA-266.

Roche’s Genentech subsidiary is terminating for undisclosed reasons its 2021 contract with Adaptimmune for the development of allogeneic T-cell therapeutics.

MaaT Pharma, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ dedicated to enhancing survival for patients with cancer, presents a summary of its oral presentation at the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation currently being hosted in Glasgow, Scotland from 14-17 April 2024.

TreeFrog Therapeutics, a cell therapy development company with its lead program in Parkinson’s Disease is presenting for the first time at the annual meeting of the American Academy of Neurology, taking place in Denver, Colorado April 13-18, 2024.

Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore together with our Chief Scientific Officer, Dr. Jerry Kanellos and Research & Development Manager, Dr. Joanne Casey will be hosting a Live Virtual Event on Tuesday, April 30 at 10am AEST / Monday, April 29 at 8pm EDT.